Tepezza, teprotumumab-trbw

About Tepezza

Tepezza (teprotumumab-trbw) was developed by Horizon Therapeutics and is now part of the Amgen portfolio following Amgen's 2023 acquisition of Horizon. The US FDA approved Tepezza in January 2020 for the treatment of thyroid eye disease, also called Graves' ophthalmopathy or thyroid-associated ophthalmopathy, in adults. The 2023 label update removed the original "active" qualifier so that Tepezza can be used regardless of disease activity or duration. Tepezza was the first medicine approved specifically for thyroid eye disease, and for many patients it offers a non-surgical option that targets the disease mechanism.

Thyroid eye disease is a serious, often disfiguring autoimmune condition that affects the muscle and fatty tissue behind the eyes. It causes eye bulging (proptosis), double vision (diplopia), eyelid retraction, redness, pain, and in severe cases compression of the optic nerve. Tepezza is not available in many countries outside the United States, which is why international patients and treating ophthalmologists frequently inquire about cross-border access. Reserve Meds coordinates US-sourced Tepezza through a documented named-patient pathway with full DSCSA serial traceability.

How Tepezza works

Tepezza is a fully human monoclonal antibody that targets and blocks the insulin-like growth factor one receptor, abbreviated as IGF-1R. In thyroid eye disease, autoantibodies activate IGF-1R together with the thyroid-stimulating hormone receptor on orbital fibroblasts. That signaling drives the production of hyaluronan, fibroblast proliferation, and inflammation in the tissues behind the eye. The result is the swelling, bulging, and double vision that define the disease.

By blocking IGF-1R, teprotumumab interrupts the signaling cascade and reduces the inflammatory and tissue-remodeling activity that produces the visible disease. In the pivotal phase three OPTIC trial, a majority of treated patients achieved a clinically meaningful reduction in proptosis (eye bulging of two millimeters or more) versus placebo, along with improvements in diplopia and disease severity scores. Many patients have reported eye bulging measurements returning toward normal during and after the eight-infusion course.

FDA indications

• Treatment of thyroid eye disease (also called Graves' ophthalmopathy) in adults.

Dosing and route

Tepezza is administered by intravenous infusion every three weeks for a total of eight infusions over approximately twenty-one weeks. The first infusion is given at 10 mg per kilogram of body weight, and the remaining seven infusions are given at 20 mg per kilogram. The initial infusion is given over ninety minutes, and subsequent infusions can be given over sixty minutes if the patient tolerated prior infusions well. The infusion must be administered in a clinical setting by a healthcare professional with the ability to manage infusion reactions and hypersensitivity.

Tepezza is supplied as a single-dose vial of lyophilized powder that is reconstituted and diluted in normal saline immediately before infusion. Storage is refrigerated between thirty-six and forty-six degrees Fahrenheit, protected from light. Reserve Meds ships every Tepezza order under validated cold-chain conditions to the infusion site nominated by the treating physician, typically a hospital pharmacy or specialty infusion clinic in the destination country.

Common side effects

The most frequently reported side effects in trials include muscle spasms, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing changes, dysgeusia (taste alteration), headache, dry skin, weight loss, and nail changes. The most clinically important risks are hearing changes (including, in some cases, persistent hearing loss), worsening of pre-existing inflammatory bowel disease, infusion reactions, and hyperglycemia, which can be significant in patients with diabetes or pre-diabetes. Pre-existing diabetes should be well-controlled before starting Tepezza, and hearing should be assessed at baseline, periodically during treatment, and after completion. Tepezza can cause fetal harm and is contraindicated in pregnancy; effective contraception is required during treatment and for six months after the last dose.

Cross-border named-patient access

Reserve Meds operates a named-patient program for Tepezza. The pathway is built for international patients who have a valid prescription from a treating physician in their home country and want a US-sourced, DSCSA-traceable supply shipped to them on a documented regulatory pathway. We do not stock inventory, we do not ship without a prescription, and we do not operate inside the US prescription market. Every shipment is patient-specific, physician-authorized, and routed through a US specialty wholesaler with full serialization on every unit.

Because Tepezza is an infused biologic delivered over eight visits across roughly five months, Reserve Meds works with the treating ophthalmologist or endocrinologist and the destination-country infusion site to align shipment timing with the infusion calendar. Reserve Meds does not replace the relationship with a treating physician. We coordinate the supply leg, the documentation leg, and the cold-chain leg. The clinical leg, including baseline audiology, glucose monitoring, infusion administration, and adverse event management, stays with the patient's physician and infusion team in the destination country.

How Reserve Meds coordinates Tepezza

1. Patient or treating physician submits a named-patient request.
2. Clinical team verifies appropriateness of Tepezza for the patient and destination country, including the planned infusion site.
3. Treating physician issues prescription and clinical justification.
4. Country-specific NPP or personal-import documentation is prepared.
5. Tepezza is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's hospital or specialty infusion clinic under validated cold-chain conditions, with continuous temperature monitoring end to end, timed against the infusion-visit schedule.